Quality of life with ablation or medical therapy for ventricular arrhythmias: A substudy of VANISH
- 30 January 2018
- journal article
- research article
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 29 (3) , 421-434
Abstract
Background/objective: We compared health‐related quality of life (HRQoL) in patients randomized to escalated therapy and those randomized to ablation for ventricular tachycardia in the VANISH trial.Methods: HRQoL was assessed among VANISH patients at baseline and 3‐, 6‐, and 12‐month follow‐up visits. Four validated instruments were used: the SF‐36, the implanted cardioverter defibrillator (ICD) Concerns questionnaire (ICDC), the Hospital Anxiety and Depression Scale (HADS), and the EuroQol five dimensions questionnaire (EQ‐5D). Linear mixed‐effects modeling was used for repeated measures with SF‐36, HADS, ICDC, and EQ‐5D as dependent variables. In a second model, treatment was subdivided by amiodarone use prior to enrollment.Results: HRQoL did not differ significantly between those randomized to ablation or escalated therapy. On subgroup analysis, improvement in SF‐36 measures was seen at 6 months in the ablation group for social functioning (63.5–69.3, P = 0.03) and energy/fatigue (43.0–47.9, P = 0.01). ICDC measures showed a reduction in ICD concern in the ablation group at 6 months (10.4–8.7, P = 0.01) and a reduction in ICD concern in the escalated therapy group at 6 months (10.9–9.4, P = 0.04). EQ‐5D measures showed a significant improvement in overall health in ablation patients at 6 months (63.4–67.3, P = 0.04).Conclusion: Patients in the VANISH study randomized to ablation did not have a significant change in quality of life outcomes compared to those randomized to escalated therapy. Some subgroup findings were significant, as those randomized to ablation showed persistent improvement in SF‐36 energy/fatigue and ICD concern, and transient improvement in SF‐36 social functioning and EQ‐5D overall health.Keywords
Funding Information
- Canadian Institutes of Health Research
- Biosense Webster
- St. Jude Medical
This publication has 17 references indexed in Scilit:
- Development of a measure of the concerns held by people with implanted cardioverter defibrillators: The ICDCBritish Journal of Health Psychology, 2006
- Validation of the EQ‐5D in patients with a history of acute coronary syndromeCurrent Medical Research and Opinion, 2005
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005
- Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated CardiomyopathyNew England Journal of Medicine, 2004
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionNew England Journal of Medicine, 2002
- Quality of Life in the Antiarrhythmics Versus Implantable Defibrillators TrialCirculation, 2002
- The Impact of the Implantable Cardioverter Defibrillator on Quality‐of‐LifePacing and Clinical Electrophysiology, 1995
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983